The FDA’s big gamble on the new Alzheimer’s drug

+Practice
In print
Analysis

The FDA’s big gamble on the new Alzheimer’s drug

The Conversation

The Conversation

Pills
Do the benefits of approving a drug before confirming it works outweigh the potential costs?

by C. Michael White, distinguished professor and head of the Department of Pharmacy Practice, University of Connecticut

The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated app